Redeye expresses disappointment following this morning's news that Xspray has received a CRL for its...
Redeye comments on the latest information regarding Karpatens lawsuit.
• Q2 should be burdened by weak PET foam market... • .
• Solid Q2 report, NAV down on MFG • Recent increase in interest rate expectations • 2023e P/CEPS at...
Redeye thinks the meaning of the verdict from the Markman hearing is unclear.
Redeye shares its preview of BONESUPPORT’s Q2 2023e results, due July 13.
- We lower 23e-'25e adj. EBITA by 6% - Conditions for IT services companies worsening - B3 trading...
- Positive net letting and higher rental levels - Floating debt with higher interest rates takes do...
- We cut '23e-'25e EBITA by 11-3% - Equity issue eases leverage - '24e FCF yield of 5.
Redeye maintains its estimates with minor changes following Nanologica’s Q2 2023 report, on which we...
- Q2: Higher growth and better margins... - driven by both Tolling and Traffic Mgmt.
Taaleri announced first closing of new flagship fund SolarWind III at EUR 286m.
Redeye ser positivt på nattens viktiga besked att Leqembi (Lecanemab) får ett fullt godkännande för ...
Redeye has a largely neutral take on Nanologica’s Q2 2023 report in terms of the financials.
NOI +31% y-o-y, +3% vs ABGSCe MFG discussions ongoing, write-down of ~EUR 31m Getting used to NOI be...
Redeye provides an update on Fantasma Games ahead of its Q2-results (due 9 Aug), where we expect a s...
NoHo Partners announced today acquisition of Swiss premium burger chain Holy Cow! with 2023E EV/oper...
Biometriska accesskort ger stor potential till relativt sett låg risk… Med höga säkerhetskrav, en ko...
Redeye provides an update as we resume coverage after CLS’ rights issue.
Redeye comments on Embracer Group’s directed issue of cSEK2bn.
